Security key
52187K200
CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (CYPH)
CUSIP: 52187K200
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 311,249
- Total 13F value
- $190,555
- Share change
- +159,508
- SEC-reported price per share
- $0.61
- Number of holders
- 7
- Value change
- +$97,644
- Number of buys
- 5
- Number of sells
- 1
- Shares outstanding
- 60,725,945
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
7
Top holders
7
CYPH full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
CYPHERPUNK TECHNOLOGIES INC. SEC filings
CYPHERPUNK TECHNOLOGIES INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 52187K200
Recent filing periods:
Ownership snapshot
Top reported holders of CYPH - CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Winklevoss Capital Fund, LLC
Disclosed value leader
BeOne Medicines Ltd.
Comparable rows
15/15
Latest evidence
31 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
13D/G row: Winklevoss Capital Fund, LLC
Showing 1-6 of 15 holder rows.
Quick read
Winklevoss Capital Fund, LLC leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Winklevoss Capital Fund, LLC's linked filing trail.
Comparable ownership
Top 5
Winklevoss Capital Fund, LLC
20%
Severns Sean Michael
11%
BeOne Medicines Ltd.
2%
James H. Cavanaugh
0.28%
Joseph Loscalzo
0.28%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Winklevoss Capital Fund, LLC |
3/4/5
13D/G
10%+ Owner
|
20%
from 13D/G
|
$10,958,327
65,466,139 shares
mixed-class rows
|
— | 08 Oct 2025 |
| Severns Sean Michael |
13D/G
|
11%
|
$2,760,000
6,000,000 shares
|
$0 | 12 Nov 2025 |
| BeOne Medicines Ltd. |
3/4/5
13D/G
10%+ Owner · BeiGene, Ltd.
|
2%
from 13D/G
|
$20,943,045
7,348,437 shares
|
— | 24 Sep 2021 |
| James H. Cavanaugh |
3/4/5
Director
|
0.28%
|
$118,274
168,963 shares
|
— | 13 Mar 2026 |
| Joseph Loscalzo |
3/4/5
Director
|
0.28%
|
$118,125
168,750 shares
|
— | 13 Mar 2026 |
| Richard Schilsky |
3/4/5
Director
|
0.28%
|
$118,125
168,750 shares
|
— | 13 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
311,249
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
37
Q2 2026 holders
7
Holder diff
-30
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend